Hagen Kulbe

Charterhouse Square
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Reproducibility of positive AGO score in predicting complete cytoreduction in recurrent low-grade ovarian cancers.

Reproducibility of positive AGO score in predicting complete cytoreduction in recurrent low-grade ovarian cancers.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 16, 2025

Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Journal: Leukemia

Published: May 07, 2024

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Journal: Leukemia

Published: February 10, 2024

Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study.

Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study.

Journal: Cancers

Published: November 09, 2023

LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.

LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.

Journal: Human pathology

Published: July 30, 2023

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.

Journal: Neoplasia (New York, N.Y.)

Published: June 22, 2023

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma.

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma.

Journal: Journal of ovarian research

Published: March 23, 2023

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients.

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients.

Journal: Cancers

Published: March 16, 2023

AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.

AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.

Journal: British journal of cancer

Published: December 04, 2022

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer.

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: July 29, 2022

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.

Journal: Journal of cancer research and clinical oncology

Published: May 03, 2022

Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.

Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.

Journal: Anticancer research

Published: January 26, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026